AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.Business Wire • 05/15/23
Teva Pharmaceutical Industries Limited (TEVA) Q1 2023 Earnings Call TranscriptSeeking Alpha • 05/10/23
Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/10/23
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat SalesInvestors Business Daily • 05/10/23
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP OutlookBusiness Wire • 05/10/23
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of ScheduleBusiness Wire • 05/09/23
MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)Business Wire • 05/04/23
U.S. Mental Health Access Program Expands Medicine Donation to Seven New StatesBusiness Wire • 05/03/23
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsBusiness Wire • 04/29/23
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023Business Wire • 04/14/23
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual MeetingBusiness Wire • 04/11/23
The Byzantine Adderall Shortage Puts Teva And Others In The Hot SeatInvestors Business Daily • 04/05/23
Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health SystemBusiness Wire • 03/27/23
Teva Pharmaceutical Industries Limited (TEVA) Barclays Global Healthcare Conference (Transcript)Seeking Alpha • 03/14/23
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementBusiness Wire • 03/13/23
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.Business Wire • 03/09/23